Barclays Reiterates an 'Overweight' on ARIAD Pharmaceuticals (ARIA); Continued Execution on Ponatinib; Preclinical Solid Tumor Data at AACR
Go back to Barclays Reiterates an 'Overweight' on ARIAD Pharmaceuticals (ARIA); Continued Execution on Ponatinib; Preclinical Solid Tumor Data at AACR| Ariad Pharmaceuticals, Inc. (NYSE: ARIA) | Delayed: 25.17 +0.35 (1.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.82 | 52 Week High | $14.34 | |||
| Open | $25.17 | 52 Week Low | $4.37 | |||
| Day High | $25.17 | P/E | N/A | |||
| Day Low | $25.17 | EPS | $-1.45 | |||
| Volume | 13 | |||||
